Ginkgo Bioworks Holdings (DNA) Cash & Equivalents Growth (1y) (2020 - 2026)
Ginkgo Bioworks Holdings (DNA) Cash & Equivalents Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 23.81% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 15.53% |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 90.42% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 17.50% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -4.13% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 71.81% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Ginkgo Bioworks Holdings | 445.24 Mn | 301.37 Mn | 16.38 Mn | -53.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.95% |
| Dec 31, 2025 | -70.23% |
| Sep 30, 2025 | -81.98% |
| Jun 30, 2025 | -72.13% |
| Mar 31, 2025 | -62.83% |
| Dec 31, 2024 | -40.52% |
| Sep 30, 2024 | -41.27% |
| Jun 30, 2024 | -33.95% |
| Mar 31, 2024 | -30.32% |
| Dec 31, 2023 | -28.25% |
| Sep 30, 2023 | -19.45% |
| Jun 30, 2023 | -19.70% |
| Mar 31, 2023 | -19.22% |
| Dec 31, 2022 | -15.11% |
| Sep 30, 2022 | -25.10% |
| Jun 30, 2022 | 483.80% |
| Mar 31, 2022 | 384.53% |
| Dec 31, 2021 | 307.04% |
| Sep 30, 2021 | 269.18% |
| Dec 31, 2020 | -23.12% |